search
Back to results

Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
insulin glulisine
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Subjects with type 2 diabetes mellitus who have been using a stable combination oral antidiabetic therapy of 2 or 3 agents in different therapeutic classes for on at least 3 months will be enrolled in this study. Inclusion Criteria: Male and female subjects 18 to 79 years of age with a diagnosis of type 2 diabetes mellitus for at least 6 months Current treatment with a stable dose of 2 oral antidiabetic agents. The oral agents must be in 2 or 3 of the following 3 different classes: Sulfonylurea: dosage greater than or equal to, one-half the maximum recommended dosage (eg, glimepiride >/= 4 mg; glipizide, including gastrointestinal therapeutic system [GITS], >/= 10 mg; glyburide >/= 10 mg; Glynase® >/=3 mg). The dosage must have been stable for at least 3 months prior to screening. Biguanide: metformin dosage ≥ 1000 mg daily, including Glucophage XR®. The dosage must have been stable for at least 3 months prior to screening. Thiazolidinedione (TZD): pioglitazone >/= 15 mg or rosiglitazone >/= 24 mg. The subject must have been using the same thiazolidinedione for at least 6 months,and the dosage must have been stable for at least 3 months prior to screening. HbA1c >/= 8.0% Fasting C-peptide concentration > 0.27 nmol/L Able and willing to perform self-monitoring of blood glucose (SMBG) up to 4 times a day Able and willing to adhere to, and be compliant with, the study protocol Able to read English or Spanish at the sixth-grade level in order to complete the subject reported outcomes component of the study Signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization Exclusion Criteria: Insulin use within the previous year History of hypoglycemia unawareness Acute or chronic, or history of, metabolic acidosis, including diabetic ketoacidosis Impaired renal function as shown by, but not limited to, serum creatinine ≥ 3mg/dL. For subjects taking metformin, serum creatinine >/= 1.5 mg/dL for males, or >/= 1.4 mg/dL for females. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 2.5 times the upper limit of normal (ULN) Clinically significant peripheral edema if subject is using a TZD History of stroke, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or angina pectoris, within the past 12 months History of, or current, congestive heart failure (New York Heart Association [NYHA] III-IV) requiring pharmacologic treatment Acute infection Any malignancy within the past 5 years, with the exception of adequately treated basal or squamous cell carcinoma or adequately treated cervical carcinoma in situ Current substance addiction or alcohol abuse or history of substance or alcohol abuse, within the past 2 years Any clinically significant renal disease (other than proteinuria) or hepatic disease Pregnant or lactating females Dementia or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study Impaired dexterity or vision rendering the subject unable to administer injections Known hypersensitivity to insulin glargine or insulin glulisine or any of the components of Lantus or Apidra Any disease or condition (including abuse of illicit drugs, prescription medications, or alcohol) that, in the opinion of the investigator or sponsor, may interfere with the completion of the study Unlikely to comply with the protocol, eg, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof, directly involved in the conduct of the protocol No subject will be allowed to enroll in this study more than once.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Experimental

    Arm Label

    1

    2

    3

    Arm Description

    Once daily: Insulin glulisine Dosing: Supper, Lunch, Breakfast Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch

    Twice daily: Insulin glulisine Dosing: Supper & Lunch, Lunch & Breakfast, Breakfast & Supper Monitoring Needed at: Bedtime & Pre-Supper, Pre-Supper & Pre-Lunch, Pre-Lunch & Bedtime

    Twice daily: Insulin glulisine Dosing: Supper, Lunch, Breakfast Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch

    Outcomes

    Primary Outcome Measures

    To show non-inferiority between treatment groups (insulin glargine plus insulin glulisine administered once a day, twice a day, or 3 times a day) in the change in glycemic control as measured by hemoglobin A1C.

    Secondary Outcome Measures

    Full Information

    First Posted
    August 23, 2005
    Last Updated
    January 10, 2011
    Sponsor
    Sanofi
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00135083
    Brief Title
    Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
    Official Title
    One Versus Two Versus Three Daily Rapid-acting Insulin Injections of APIDRA (Insulin Glulisine) as add-on to Lantus® and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-label Clinical Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    August 2004 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    November 2007 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Sanofi

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to show the non-inferiority of insulin glulisine administered with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c (HbA1c), from baseline to study week 24.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus, Type 2

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    347 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Description
    Once daily: Insulin glulisine Dosing: Supper, Lunch, Breakfast Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch
    Arm Title
    2
    Arm Type
    Experimental
    Arm Description
    Twice daily: Insulin glulisine Dosing: Supper & Lunch, Lunch & Breakfast, Breakfast & Supper Monitoring Needed at: Bedtime & Pre-Supper, Pre-Supper & Pre-Lunch, Pre-Lunch & Bedtime
    Arm Title
    3
    Arm Type
    Experimental
    Arm Description
    Twice daily: Insulin glulisine Dosing: Supper, Lunch, Breakfast Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch
    Intervention Type
    Drug
    Intervention Name(s)
    insulin glulisine
    Intervention Description
    Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below. Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below. Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below.
    Primary Outcome Measure Information:
    Title
    To show non-inferiority between treatment groups (insulin glargine plus insulin glulisine administered once a day, twice a day, or 3 times a day) in the change in glycemic control as measured by hemoglobin A1C.
    Time Frame
    From baseline to study week 24.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    79 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Subjects with type 2 diabetes mellitus who have been using a stable combination oral antidiabetic therapy of 2 or 3 agents in different therapeutic classes for on at least 3 months will be enrolled in this study. Inclusion Criteria: Male and female subjects 18 to 79 years of age with a diagnosis of type 2 diabetes mellitus for at least 6 months Current treatment with a stable dose of 2 oral antidiabetic agents. The oral agents must be in 2 or 3 of the following 3 different classes: Sulfonylurea: dosage greater than or equal to, one-half the maximum recommended dosage (eg, glimepiride >/= 4 mg; glipizide, including gastrointestinal therapeutic system [GITS], >/= 10 mg; glyburide >/= 10 mg; Glynase® >/=3 mg). The dosage must have been stable for at least 3 months prior to screening. Biguanide: metformin dosage ≥ 1000 mg daily, including Glucophage XR®. The dosage must have been stable for at least 3 months prior to screening. Thiazolidinedione (TZD): pioglitazone >/= 15 mg or rosiglitazone >/= 24 mg. The subject must have been using the same thiazolidinedione for at least 6 months,and the dosage must have been stable for at least 3 months prior to screening. HbA1c >/= 8.0% Fasting C-peptide concentration > 0.27 nmol/L Able and willing to perform self-monitoring of blood glucose (SMBG) up to 4 times a day Able and willing to adhere to, and be compliant with, the study protocol Able to read English or Spanish at the sixth-grade level in order to complete the subject reported outcomes component of the study Signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization Exclusion Criteria: Insulin use within the previous year History of hypoglycemia unawareness Acute or chronic, or history of, metabolic acidosis, including diabetic ketoacidosis Impaired renal function as shown by, but not limited to, serum creatinine ≥ 3mg/dL. For subjects taking metformin, serum creatinine >/= 1.5 mg/dL for males, or >/= 1.4 mg/dL for females. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 2.5 times the upper limit of normal (ULN) Clinically significant peripheral edema if subject is using a TZD History of stroke, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or angina pectoris, within the past 12 months History of, or current, congestive heart failure (New York Heart Association [NYHA] III-IV) requiring pharmacologic treatment Acute infection Any malignancy within the past 5 years, with the exception of adequately treated basal or squamous cell carcinoma or adequately treated cervical carcinoma in situ Current substance addiction or alcohol abuse or history of substance or alcohol abuse, within the past 2 years Any clinically significant renal disease (other than proteinuria) or hepatic disease Pregnant or lactating females Dementia or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study Impaired dexterity or vision rendering the subject unable to administer injections Known hypersensitivity to insulin glargine or insulin glulisine or any of the components of Lantus or Apidra Any disease or condition (including abuse of illicit drugs, prescription medications, or alcohol) that, in the opinion of the investigator or sponsor, may interfere with the completion of the study Unlikely to comply with the protocol, eg, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof, directly involved in the conduct of the protocol No subject will be allowed to enroll in this study more than once.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Karen Barch, B.S.
    Organizational Affiliation
    Sanofi
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    21324825
    Citation
    Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract. 2011 May-Jun;17(3):395-403. doi: 10.4158/EP10323.OR.
    Results Reference
    derived

    Learn more about this trial

    Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus

    We'll reach out to this number within 24 hrs